Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. BVAXF


Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(372)
•••
Post by moneywagonon Oct 27, 2022 10:22am
85 Views
Post# 35052918

BIOV 700K INCOMING!! JUST THE FACTS~ARE YOU LOCKED & LOADED?

BIOV 700K INCOMING!! JUST THE FACTS~ARE YOU LOCKED & LOADED?
C:BIOV - BioVaxys Technology Corp. - https://biovaxys.com
Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr Open-Hi-Lo Year Hi-Lo Last Tr News Delay
BIOV - C   9.5 0.23 · 0.235 1.0 0.23 -0.01 -4.2 672.8 154 194 0.255  0.26  0.225 0.395  0.085 10:02:45 Oct 14 15 min RT 2¢
CSE - C 9.5 0.23 · 0.235 1.0 0.23 -0.01 -4.2 210.5 49 64 0.255  0.26  0.23 0.395  0.085 10:02:45   15 min
NEO ATS - U   0.23 -0.01 -4.2 373.5 85 93 0.24  0.26  0.225   10:02:45   15 min
Omega - O   0.23 -0.01 -4.2 62.0 14 23 0.25  0.26  0.23   10:02:45   15 min
CX2 - H   0.245 +0.005 2.1 26.5 6 11 0.225  0.245  0.225   10:01:13   15 min
CXD - D   0.24     0.0   1        Jul 04   15 min
TriAct - M   0.24     0.3   2            15 min

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities